Varegacestat - Immunome
Alternative Names: AL-102; BMS 986115; WHG-626Latest Information Update: 18 Dec 2025
At a glance
- Originator Bristol-Myers Squibb
- Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; Novartis
- Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Yes - Unspecified; Solid tumours
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Fibroma
- No development reported Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 15 Dec 2025 Immunome announces intention to submit NDA to US FDA for Desmoid tumours in Q2 of 2026
- 15 Dec 2025 Efficacy and adverse events data from a phase II/III RINGSIDE trial in Desmoid tumours released by Immunome
- 31 Jul 2025 Varegacestat - Immunome receives Orphan Drug status in European Union